Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance

Area of Science:

• Microbiology
• Genetics
• Biotechnology

Background:

• Antimicrobial resistance (AMR) poses a significant global health threat, driving the need for innovative treatment strategies.
• The CRISPR-Cas system, a bacterial adaptive immune mechanism, presents a potential avenue for developing targeted antimicrobials.
• Existing antimicrobial approaches face limitations, particularly against drug-resistant bacteria.

Purpose of the Study:

• To review the recent advancements in utilizing CRISPR-Cas systems as antimicrobials against AMR pathogens.
• To explore the application of different CRISPR-Cas types (I, II, and VI) for eradicating resistant bacteria and plasmids.
• To identify and discuss the challenges and potential solutions for implementing CRISPR-Cas based antimicrobials.

Main Methods:

• Literature review focusing on studies published in recent years concerning CRISPR-Cas applications in antimicrobial development.
• Analysis of research employing type I, type II, and type VI CRISPR-Cas systems for targeting AMR bacteria and plasmids.
• Synthesis of information on the hurdles encountered in the clinical or practical application of these systems.

Main Results:

• CRISPR-Cas systems have demonstrated potential in selectively targeting and destroying bacterial genomes, including AMR pathogens and plasmids.
• Various CRISPR-Cas types show promise in combating infectious diseases caused by resistant microorganisms.
• Significant challenges remain in the translation of CRISPR-Cas antimicrobials from laboratory research to clinical practice.

Conclusions:

• The CRISPR-Cas system is a promising candidate for next-generation antimicrobials, particularly against AMR pathogens.
• Further research and development are crucial to overcome existing obstacles and realize the full therapeutic potential of CRISPR-Cas antimicrobials.
• Addressing challenges will pave the way for effective treatments against drug-resistant infections.